André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.

Slides:



Advertisements
Similar presentations
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
Advertisements

Steroids In caRdiac Surgery (SIRS) Trial
Is this the “spioenkop” for CABG?
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
5 Years Results of Off-Pump VS On-Pump CABG 5 Years Results of Off-Pump VS On-Pump CABG Prospective Non-randomized Comparative Study Piya Cherntanomwong*,
Population Health Research Institute Hamilton Health Sciences/McMaster University Hamilton, Canada Steroids In caRdiac Surgery (SIRS) Trial SIRS was funded.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Simultaneous Coronary Artery Bypass and Carotid Endarterectomy Ye zhidong, Liu Peng Department of Cardiovascular Surgery China-Japan Friendship Hospital.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Clinical Outcomes with Newer Antihyperglycemic Agents
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
An International Randomized Trial of Early Versus Delayed Invasive Strategies in Patients with Non-ST Segment Elevation Acute Coronary Syndromes TIMACS.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
1 HOT LINE PRESENTATION World Congress of Cardiology 2006 Barcelona, Spain September 5, 2006 Warfarin Antiplatelet Vascular Evaluation PAD Patients.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Lund – Malmö, SWEDEN. Is the Era of Off-pump Surgery over? ARASH MOKHTARI, MD, PHD.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Rivaroxaban in stable peripheral or carotid artery disease
David J McCormack MFSTEd FRCSEd (CTh) Advanced Clinical Fellow
The German Off-Pump Coronary Artery Bypass Grafting in
Clinical Outcomes with Newer Antihyperglycemic Agents
Single IMA {Single Arterial}
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Andre Lamy on behalf of the COMPASS Investigators
Jeff Macemon Waikato Cardiothoracic Unit
Dabigatran in myocardial injury after noncardiac surgery
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Dr. PJ Devereaux on behalf of POISE Investigators
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
for the REGROUP Trial Investigators
Dr. PJ Devereaux on behalf of POISE Investigators
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Atlantic Cardiovascular Patient Outcomes Research Team
Presenter Disclosure Information
Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.
Presentation transcript:

André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures : CORONARY was funded by a grant from the Canadian Institutes of Health Research (CIHR). CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study

Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. Majority of prior trials had few events and short follow-up. Meta-analyses of 59 trials involving 8961 pts – reduction in early strokes with off-pump – no differences in other major CV outcomes. Background 2

79 centers in 19 countries 4,752 patients recruited between (November 2006 October 2011) Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada The data was monitored by independent DSMB Funded by Canadian Institutes of Health Research CORONARY Trial Organization 3

-Off pump CABG compared to on-pump CABG would reduce major clinical events in short-term (30 Days) -Benefits maintained in long-term (5 yrs) Study Hypotheses 4

Inclusion Criteria – Isolated CABG with median sternotomy – One of the following: 1.Peripheral vascular disease 2.Cerebrovascular disease 3.Renal Insufficiency 4.Age ≥ 70 years 5.Age with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF ≤ 35%) 6.Age with at least two of the above risk factors Exclusions – Additional cardiac procedure planned – Contraindications to off-pump or on-pump CABG – Emergency or re-do CABG Inclusion/Exclusion Criteria 5

Surgical expertise-based randomization – > 2 years of experience as staff cardiac surgeon and – > 100 cases of one or both techniques – Trainees were not allowed to be primary operators Qualifications of Surgeons 6

1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization results presented today 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 2016) Primary Outcomes 7

Secondary Efficacy Outcomes - Components of 1st co-Primary Outcome - Cost Effectiveness* Other Outcomes - Recurrent angina, blood transfusions and CV mortality - Composite of total mortality, stroke, non fatal MI, new renal failure at hospital discharge - Quality of life, neurocognitive function* Other Outcomes – 30 Days 8 * Further reporting

1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization 80% power to detect a 28% risk reduction 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary re-revascularization over 5 yrs of follow-up (expected 2016) 90% power to detect a 20% risk reduction Statistical Power 9

Follow-up at 30 Days: 100% patients All events adjudicated Data: 99.9 % clean Data Quality and Completeness 10

OFF-PUMP (n = 2375) ON-PUMP (n = 2377) Mean Age (years) Males (%) Prior MI Previous Stroke Peripheral Arterial Disease Congestive Heart Failure Urgent Surgery Euroscore 0 – 2 3 – 5 > Baseline Characteristics 11

OFF-PUMP (n = 2375) % ON-PUMP (n = 2377) % Left Main Triple Vessel Double Vessel Single Vessel Baseline Disease – Pre-op Angiogram 12

Operation Details Randomized (ITT Analyses) Off PumpOn Pump CABG ≤ 30 days2148 (90.4%)2183(91.8%) Cross-overs184 (7.8%)150 (6.4%) Off Pump % On Pump % RR95% CIp value Incomplete revascularization Operating room (median hrs)4.04.2<0.001 Initial ventilation (median hrs) <0.001

OFF-PUMP (n = 2375) ON-PUMP (n = 2377) p-value n%n% CABG Completed Total grafts performed3.03.2<0.001 CONDUIT LIMA or RIMA Saphenous Vein <0.001 Conduits 14

OFF-PUMP (n = 2375) % ON-PUMP (n = 2377) % p value Any Blood Transfusion <0.001 Antifibrinolytics <0.001 Re-operation for bleeding Peri-operative Transfusions and Bleeding 15

1 st Co-Primary Outcome (30 Days) 16 Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death, Stroke, MI, Renal Failure

1 st Co-Primary Outcome (30 Days) 17 Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death, Stroke, MI, Renal Failure Components Death Stroke Non Fatal MI New Renal Failure

Death/MI/Stroke/New Renal Failure at 30 Days 18 HR % CI p value 0.59 Days of Follow-up Cumulative Event Rate Off Pump On Pump # at Risk OFF ON

Other Outcomes at 30 days 19 Off Pump % On Pump % Hazard Ratio 95% CIp value Angina PCI Re-do CABG PCI/Re-do CABG All re-operations (re-do CABG) All re-operations/Re-do CABG/PCI

Off Pump % On Pump % Relative Risk 95% CIp value Respiratory Infection or failure Acute Kidney Injury AKIN Stage RIFLE risk New Renal Failure requiring Dialysis Other Outcomes at 30 days 20 Acute Kidney Injury Network (AKIN): absolute increase in serum creatinine value ≥27 µmol/L OR an increase of ≥150 % from the baseline serum creatinine value Risk, Injury, Failure, Loss and End-stage Renal Disease (RIFLE): increase of ≥150 % from the baseline serum creatinine value

Primary Outcome at Hospital Discharge 21 Off Pump % On Pump % Hazard Ratio 95% CI p value Tertiary Outcome Death/MI/Stroke/Renal Failure Components Death Stroke Non Fatal MI New Renal Failure

Subgroups (1) 22

23 Subgroups (2)

At 30 days there was no difference in the primary outcome between Off pump CABG and On pump CABG. Off-pump was associated with: – Less transfusions and re-operation for bleeding – Less acute kidney injury – Less respiratory infections/failure – More early revascularizations Conclusions 24

In experienced hands, both procedures are reasonable options based on short-term results The difference in morbidity that was detected in the 30 days results may or may not lead to significant differences during the long-term follow-up that we are conducting Implications 25

A. Lamy (Co-PI)P.J. DevereauxJ. Murkin D.P. TaggartD. PrabhakaranR.J. Novick A.R. AkarS.E. FremesE. Paolasso A. AvezumS. HuL. Piegas R. CartierF. LanasZ. Straka S. ChocronP.J. LopezS. Yusuf (co-PI) Steering Committees 26

Final Recruitment by Country 4752 patients from 79 sites in 19 countries 27 Argentina (257) Canada (830) Brazil (358) Netherlands (27) Sweden (56) United Kingdom (227) France (4) Italy (48) USA (68) Czech Republic (298) Estonia (91) Turkey (132) Ukraine (11) Colombia (57) Australia (29) Uruguay (34) China (781) India (1307) Chile (137)

28